Skip to main content
Premium Trial:

Request an Annual Quote

This Won't Hurt a Bit

Premium

Getting tested for bladder cancer — which involves the use of a catheter — can be rather invasive and somewhat painful, says Forbes' Peter Cohan. So biotech startup Predictive Biosciences says it has come up with a better way. The company has commercialized a urine-based, non-invasive cancer detection technology invented by two researchers that uses a combination of protein and DNA biomarkers to help clinicians diagnose bladder and prostate cancer, Cohan says. Because of the potential size of the target markets — a $3 billion bladder cancer detection market and a $3 billion prostate cancer detection market — Predictive Biosciences has raised $57 million in venture capital. The company doesn't sell its diagnostics to urologists, it does test urine samples from patients at its own lab, Cohan adds. The company acquired an anatomic pathology lab in Cleveland in January 2010, focused on urology.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.